Case report indicates regression of coronary atherosclerosis in patients with cardiomyovasculopathy — Evidence Review

A new case report from Japanese researchers suggests that the supplement tricaprin may help reverse a rare, treatment-resistant form of heart artery disease, though most previous research finds limited benefits for supplements in cardiovascular health. Related studies generally show that common supplements, unlike tricaprin in this case, have not demonstrated consistent cardiovascular benefits in large trials, and more evidence is needed to confirm these new findings from Osaka University.

• While many large-scale studies and meta-analyses report minimal or no cardiovascular benefit from most supplements (such as vitamins, antioxidants, and minerals), this new tricaprin case report stands out by documenting the regression of atherosclerotic lesions in two patients with a specific, rare disease mechanism 1 5 11.
• The majority of related studies emphasize that supplement-based interventions often fail to reduce major cardiovascular events or mortality, with only a few exceptions (e.g., folic acid, omega-3 fatty acids), and even those findings are subject to ongoing debate about clinical significance 1 2 5.
• This new approach—targeting intracellular triglyceride metabolism in vascular cells—differs from the cholesterol-lowering focus of most prior therapies and research, potentially opening a novel therapeutic avenue for patients with unique pathophysiology resistant to standard treatments 8 6 10.

Study Overview and Key Findings

Heart disease, particularly coronary artery disease (CAD), remains the leading cause of death worldwide. While lowering blood cholesterol is a well-established strategy for slowing or reversing CAD, some patients fail to respond to conventional treatments. The Osaka University case report is noteworthy because it examines a rare subtype of CAD—triglyceride deposit cardiomyovasculopathy (TGCV)—and documents marked improvement in arterial health following supplementation with tricaprin, a dietary fat, rather than traditional cholesterol-lowering drugs. The study’s significance lies in its focus on a previously under-recognized mechanism of disease and its potential to inform new therapeutic approaches for difficult-to-treat patients.

Property	Value
Study Year	2022
Organization	Osaka University
Journal Name	European Heart Journal
Authors	Ken-ichi Hirano, Masahiro Higashi, Kenichi Nakajima
Population	Patients with triglyceride deposit cardiomyovasculopathy
Sample Size	2 patients
Methods	Case Report
Outcome	Regression of coronary atherosclerosis, symptom relief
Results	Both patients showed marked regression of atherosclerotic lesions.

Literature Review: Related Studies

To assess how the new findings fit into the broader landscape of supplement-based cardiovascular interventions, we searched the Consensus database, which contains over 200 million research papers. The following search queries were used to identify relevant studies:

1. heart disease supplement effects
2. atherosclerosis regression treatments
3. cardiovascular health supplements efficacy

Summary Table: Key Topics and Findings

Topic	Key Findings
Do dietary supplements reduce cardiovascular risk or events?	• Most vitamin, mineral, and antioxidant supplements show no significant reduction in cardiovascular events or mortality in large meta-analyses 1 5 11 12. • Some evidence supports specific benefits for folic acid (stroke prevention) and omega-3 fatty acids (lowering MI and CHD risk), but benefits are modest and sometimes dose-dependent 1 2 5.
Can atherosclerosis regression be achieved with non-conventional interventions?	• Intensive cholesterol-lowering therapy (e.g., statins, PCSK9 inhibitors) can induce atherosclerotic plaque regression in a subset of patients, but such regression is not universal 8 9. • Targeting inflammatory pathways or promoting anti-inflammatory immune cell phenotypes (e.g., M2 macrophages, regulatory T cells) may facilitate plaque regression beyond lipid-lowering alone 6 7 10.
What mechanisms are involved in supplement-based effects on cardiovascular health?	• Supplements may influence cardiovascular risk factors (e.g., blood pressure, lipids, inflammation), but effects are generally small and inconsistent across different supplement types 4 5. • Few studies have explored intracellular fat metabolism or triglyceride processing within vascular cells as a therapeutic target, making the tricaprin case report a novel addition to the literature 4 6.
Are there risks or adverse effects associated with supplement use in heart disease?	• Some supplements, such as combined calcium and vitamin D, may increase the risk of stroke; antioxidant mixtures and niacin (with statins) have been associated with increased all-cause mortality in some analyses 1 3 5. • Overall, the benefit-risk profile of most supplements does not support their widespread use for cardiovascular prevention outside specific clinical indications 1 3 5 11.

---

Do dietary supplements reduce cardiovascular risk or events?

The majority of large-scale meta-analyses and systematic reviews conclude that most dietary supplements—including multivitamins, antioxidants, vitamin D, and minerals—do not consistently reduce the risk of cardiovascular events, heart attacks, or mortality. Some exceptions, such as folic acid and omega-3 fatty acids, show preventive benefits for select outcomes like stroke or myocardial infarction, but the clinical impact is generally modest. In contrast, the new tricaprin case report highlights a unique context (TGCV) where a supplement appears to have substantial benefit, differing from the broad population focus of most prior research.

• Randomized controlled trials and meta-analyses have found no significant benefit from most vitamin or antioxidant supplements in preventing major cardiovascular outcomes 1 5 11.
• Folic acid and B vitamins may reduce the risk of stroke, while omega-3 fatty acids can lower risk for heart attack and CHD events in a dose-dependent fashion, but these effects are modest and not universal 1 2 5.
• Some supplement combinations, such as calcium plus vitamin D, may even elevate stroke risk; thus, the risk-benefit profile must be carefully considered 5.
• The new study differs by focusing on a specific, rare disease mechanism and a supplement (tricaprin) that targets intracellular triglyceride metabolism, not addressed in previous trials 1 5.

Can atherosclerosis regression be achieved with non-conventional interventions?

Achieving regression of atherosclerosis remains an important but challenging goal. High-intensity lipid-lowering therapies, such as statins and PCSK9 inhibitors, can induce plaque regression in a proportion of patients, but not all respond. Recent research also points to inflammation and immune cell modulation as promising targets for regression. The tricaprin case report is notable for demonstrating regression through enhanced intracellular fat metabolism—a mechanism distinct from conventional therapies.

• High-intensity cholesterol-lowering therapy can produce "triple regression" (plaque volume, lipid content, and cap thickness) in about one-third of patients, leading to improved outcomes 8.
• Experimental models have shown that regression is possible via diet changes and metabolic interventions, but applying these findings to humans remains complex 9.
• Modulating immune responses, especially by increasing anti-inflammatory cell types, may promote regression and vascular repair beyond lipid-lowering 6 7 10.
• The tricaprin study introduces a new mechanism—stimulating intracellular triglyceride breakdown—that may be relevant for subpopulations with unique metabolic defects 8 9.

What mechanisms are involved in supplement-based effects on cardiovascular health?

Most supplement-based interventions influence cardiovascular risk factors by modestly lowering blood pressure, improving lipid profiles, or reducing inflammation. However, these effects are generally small and not linked to major reductions in clinical events in the general population. The tricaprin case study is unique in targeting triglyceride metabolism within vascular cells, an area with little prior research.

• Vitamin D supplementation may lower blood pressure, improve lipid profiles, and reduce inflammation, but these changes are typically minor and of uncertain clinical significance 4.
• Supplements rarely address the underlying pathophysiology of atherosclerosis at the cellular level (e.g., intracellular fat metabolism) 4 6.
• Most previous interventions target serum cholesterol or systemic inflammation, not intracellular triglyceride breakdown in vascular smooth muscle cells, as in the tricaprin report 4 6.
• The novelty of the current study lies in its focus on a previously unaddressed mechanism (intracellular triglyceride lipolysis) in a specific disease context 6.

Are there risks or adverse effects associated with supplement use in heart disease?

While some supplements are safe, others may carry risks. Meta-analyses have identified increased stroke risk with combined calcium and vitamin D supplementation and elevated all-cause mortality with antioxidant mixtures or niacin (when combined with statins). These findings underscore the need for rigorous evaluation of supplement safety and efficacy before widespread use.

• Calcium plus vitamin D supplementation has been linked to an increased risk of stroke in some analyses 3 5.
• Antioxidant mixtures and niacin (with statins) may increase all-cause mortality, suggesting potential harm from indiscriminate supplement use 1 5.
• Most vitamin and mineral supplements have not demonstrated clear benefits for cardiovascular prevention and may carry unanticipated risks in certain populations 1 3 5 11.
• The new tricaprin case report involved only two patients, so safety and broader efficacy remain unclear and must be established in larger studies 1 5.

Future Research Questions

Although the new case report presents promising results for a rare, treatment-resistant form of coronary artery disease, it is based on only two patients. Larger studies are needed to confirm these preliminary findings, understand the broader applicability of tricaprin, and clarify its mechanism of action. Additional research is also warranted to compare this approach to existing therapies and assess long-term outcomes and safety.

Research Question	Relevance
Does tricaprin supplementation improve arterial health in broader populations with coronary artery disease?	The current evidence is limited to two case reports with TGCV; larger and more diverse studies are needed to determine if benefits extend to typical CAD patients 1 5.
What are the long-term outcomes and safety profiles of tricaprin supplementation in cardiovascular patients?	Previous supplement trials have revealed unexpected risks (e.g., stroke, mortality) with prolonged use; sustained follow-up is essential to assess both efficacy and safety 1 3 5.
How does tricaprin-induced triglyceride lipolysis mechanistically differ from cholesterol-lowering therapies?	Understanding the precise cellular and molecular pathways could help identify which patients are most likely to benefit and inform combination therapy strategies 6 8.
Is tricaprin effective in patients with other forms of treatment-resistant atherosclerosis?	Many individuals with atherosclerosis do not respond to standard therapies; research should explore whether tricaprin benefits extend to other hard-to-treat cases 8 9.
What are the potential interactions between tricaprin and other cardiovascular medications?	Drug-supplement interactions have sometimes led to adverse effects in past studies (e.g., niacin with statins); it is important to evaluate tricaprin alongside common cardiac medications 1 5.